The statements within this website are for infomational purposes only: Disclaimer

Berna Biotech AG

Company Information
Address Rehhagstrasse 79
3018 Bern
Country Switzerland
Phone +41 (0) 31 980 61 11
Business Sector Biotechnology
Brief Overview Berna Biotech AG is a biotechnology company specialised in the development and production of immunobiological preparations, mainly viral and bacterial vaccines. The firm was founded in 1898 under the name of Schweiz. Serum- und Impfinstitut Bern.
Chief Executive Officer Kuno Sommer
Chief Financial Officer Rolf Gasser
Chairman of the Board Peter Giger
Auditors KPMG Fides Peat
No. of Employees 698
Going Public
Exchange Swiss Exchange
IPO Date June 26, 2001
Share Identification Number 1246277
Symbol BBIN
Subscription Period 06,26,2001 to 07,06,2001
Lead Underwriter Lombard Odier & Cie.
Underwriters Berner Kantonalbank
Total No. of Shares in Issue after Going Public 1,000,000
No. of Offered Shares 1,000,000
Total No. of Issued Share 100%
Firm Offer Price CHF 912
Expected Market Cap. CHF 912 Mio.
First Day Close CHF 880
Numbers (in 1000 CHF)
Last Fiscal Year End Date Prior to Going Public December 31, 2000
Change Compared to Prior Year
Turnover 2000
180,562 0.1%
Turnover 1999
Change Compared to Prior Year
Operating Profit, EBIT 2000
174,192 2.2%
Operating Profit, EBIT 1999
Change Compared to Prior Year
Profit Before Tax 2000
4,955 -52.7%
Profit Before Tax 1999
Change Compared to Prior Year
Company Profit 2000
Company Profit1999
Company Profit 2000 reflects -12.7 % of Turnover
Company Profit 1999 reflects 4 % of Turnover
Equity on Last Balance Date 176,975
Total Assets 264,248
Ratio of Equity to Total Capital on Balance Date 67 %
Last Return on Equity (ROE) -12.9 %
Prior to going public, shares of the company were traded outside an institutional stock exchange.

Capital inrease of 200'000 shares at a price of CHF 760.-. Holders of four shares prior to the capital increase posess a right to purchase one new share. The related rights are traded from June 26 until July 6. Dead line for subsription for new shares ends July 9.

Extraordinary costs of CHF 27.5 Mio for reorganisation during the last fiscal period.